Six Questions to Ask Before You Trust a Healthcare AI Tool

A clinical AI tool deserves your trust only when you can answer six plain questions about it: what it is meant to do, what evidence supports its headline claim, who it was tested on, whether a clinician can see how it reasons, how it will be watched after go-live, and who answers for it when it is wrong. If those answers are not clean, the safer decision is to wait rather than to sign. The same six questions work whether the product is a chatbot, a triage engine, or a decision-support system wired into the record.

None of this assumes bad intent. Most teams building these tools are careful and are trying to help. The checklist is not a way to catch anyone out; it is a way to protect patients and, just as usefully, to give a genuinely good tool the scrutiny that lets you stand behind it later. Accuracy on a benchmark is one ingredient of trust, not the whole recipe.

Key points#

• Trust rests on six questions: purpose, evidence, validation population, transparency, ongoing monitoring, and accountability. If a vendor cannot answer all six cleanly, wait.
• Match the strength of evidence to the size of the decision. A benchmark score is the weakest signal; external testing on unseen data is stronger; a prospective study with a comparison group and real outcomes is strongest.
• A model can score well on the patients it learned from and slip on yours, because populations differ in age, other conditions, and how data was recorded. Who sat in the validation set matters.
• Evaluation does not stop at purchase. Models drift, so a written monitoring plan, naming what is measured, how often, by whom, and what triggers a pause, belongs on paper before anyone signs.

Start with purpose, not performance#

Nearly every later confusion traces back to skipping the first question, so begin there. Ask the vendor to state, in one sentence, the clinical question the tool answers and the patients it answers it for. A tool that "supports diabetes care" is not a claim anyone can test. A tool that "flags adults with type 2 diabetes who are likely to miss their next HbA1c target, so a clinician can reach out sooner" is a claim you can hold up to evidence.

Purpose defines the test. A frequent trap is buying a tool validated for one job and then using it for a neighboring one. A model that sorts chest pain in an emergency department is not automatically safe for phone triage from home, even though both get called "triage." A narrow purpose can be checked against data; a vague purpose usually hides the gap where the trouble lives.

Weigh the evidence against the stakes#

Once you know what the tool claims to do, ask for proof that fits the weight of the decision. Think of it as a ladder. The bottom rung is internal benchmark performance: the model scored well on a slice of its own training data it was held back from. That shows it can recognize familiar patterns, not that it improves care. The middle rung is external validation, where the tool was tested on data from a setting it never saw during development. The top rung is a prospective study in which the tool was actually used in care and outcomes were compared against a control group.

Ask directly where the tool was measured against what clinicians do today, and what changed as a result. A registered study with a real comparator, endpoints set in advance, and more than one site lets you say the tool helped, rather than only that it launched. Not every product needs a randomized trial, but the evidence should scale with the trust you are being asked to extend. Reporting standards such as TRIPOD+AI exist precisely so that these claims can be described in a way others can check.

Ask who was in the validation set#

This is the question most often skipped and the one that most reliably breaks tools in the field. A model can perform beautifully on the population it learned from and degrade on yours for reasons that have nothing to do with its code. Patients differ in age, in the other conditions they carry, and in how their information was recorded from one system to the next. A pattern that holds firmly in one group does not always carry over to another, a point epidemiology keeps proving across settings. A number earned on people unlike your patients is not a number you inherit.

So ask who was in the validation set, how closely those people resemble the patients you treat, and whether the tool was tested outside the walls of the institution that built it. A tool proven only inside its developer's own environment may be leaning on local habits and data formats rather than on anything that travels.

Insist on clinical inspectability#

Transparency does not mean the vendor hands over the model's internal weights. It means that, for a given patient, a clinician can understand enough about why the tool said what it said to decide whether to believe it. A recommendation no one can question tends to get over-trusted on a bad day and dismissed on a good one.

The workable standard is not full mathematical explainability, which is often impossible, but clinical inspectability: the tool shows the factors driving its output in terms a clinician recognizes, and it makes its uncertainty visible instead of wrapping every answer in the same flat confidence. Ask to see exactly what appears on screen at the moment of decision.

Plan for life after go-live#

Approval and purchase are the start of a tool's working life, not the end of its evaluation. Models drift. Patients change, a lab swaps one assay for another, an upstream system gets reconfigured, and a tool that was accurate on launch day slowly stops being accurate with no alarm going off. Work published in JAMA Network Open in 2025 describes how such data shifts can be detected and corrected, which is only possible if someone is looking.

A serious answer names what will be measured, how often, who reviews it, and what threshold triggers a pause, much the way a pharmacy keeps watching a drug already on the shelf. If the plan ends at the sale, you are buying a snapshot and hoping it holds.

Settle accountability before deployment#

Every tool will eventually be wrong about someone. The question is not whether, but who answers for it, and that belongs in writing before deployment. Accountability has two halves that buyers often blur. The clinical half keeps the responsible clinician as the decision-maker, with the tool supporting judgment rather than replacing it. The vendor half sets clear lines for reporting a suspected error and marks where the developer's responsibility ends. A tool that presents itself as autonomous while leaving liability with the clinician is a mismatch you want to find now, on paper, not later in a case review. Guidance from the World Health Organization points the same direction, treating health AI as something that needs stated purpose, evidence, and a named party who is answerable, not just working code.

Run the six questions in order and they build on one another, since each answer sets up the next. A tool that clears all six is one you can explain to a patient with a straight face.